Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.

• Status: Completed
• Trial end date: 2015-01-01

Summary

Aim of the study is to investigate the short-term growth in children with asthma aged 5-11 years in treatment with fluticasone propionate / formoterol spray (flutiform®) 200/20 micrograms per day

• Phase: Phase 2

Details

• Lead Sponsor: Mundipharma Research Limited
• Treatments: Beclomethasone; Fluticasone